MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc reported a sharp swing to profitability for the six months ended June 30, 2026, driven by major partnering deals. Total revenue rose to $321.7 million from $5.6 million a year earlier, including $204.6 million of license revenue and $105.2 million of service revenue from related parties. Net income attributable to shareholders was $114.4 million versus a $78.8 million loss in 2025, and shareholders’ equity improved to $215.8 million from a deficit.
Cash, cash equivalents and restricted cash increased to $145.4 million, helped by equity raises and $100 million of royalty notes, while operating activities used $20.7 million of cash. Results include a $71.9 million equity-method loss from the new Reogen collaboration and a $25 million cash payment to reacquire full rights to the RPGR gene therapy from Janssen. Management states that current profitability is primarily due to non-recurring transactions and continues to expect substantial future losses as it advances its genetic medicines pipeline.
MeiraGTx Holdings plc reported a sharp improvement in results for the quarter ended June 30, 2026, driven by large collaboration and licensing revenues. Total revenue was $321.4 million, up from $3.7 million a year earlier, including $204.6 million of license revenue and $104.9 million of related-party service revenue largely tied to J&J/Reogen transactions and Lilly manufacturing services.
Operating expenses rose to $77.0 million, mainly from higher research and development spending of $57.8 million related to reacquiring bota-vec from J&J and advancing the AAV2-hAQP1 program. Despite non-operating charges, including a $71.9 million loss on an equity method investee and a $5.2 million loss on a derivative liability linked to Oberland Capital, net income attributable to shareholders reached $160.7 million, versus a $38.8 million loss in the prior-year quarter.
As of June 30, 2026, MeiraGTx held $143.2 million in cash and cash equivalents and reported total assets of $396.4 million and shareholders’ equity of $215.8 million. The company expects its current cash plus proceeds and payments from Oberland Capital and Hologen to fund operations into the second half of 2028, excluding potential milestone receipts from Lilly.
MeiraGTx Holdings plc CFO & COO Richard Giroux sold 56,000 Ordinary Shares on July 21, 2026 at a $12.51 weighted average price, with individual trades executed between $12.00 and $12.63 per share. The reported price is a weighted average, reflecting multiple sale transactions.
The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following these transactions, Giroux is reported as directly holding 908,530 Ordinary Shares, with additional indirect holdings of 5,152 shares by his spouse and 85,000 shares by Aigle Healthcare Partners III LLC.
An affiliate of MGTX has filed to potentially sell up to 56,000 ordinary shares through Merrill Lynch on the NASDAQ market, with an aggregate market value of $700,560, based on a share balance of 92,609,516 ordinary shares outstanding. The shares proposed for sale arise from Incentive Compensation Stock Grants dated September 7, 2018 (1,569 shares) and December 7, 2018 (54,431 shares), and are listed for a proposed sale date of July 21, 2026.
MeiraGTx Holdings plc chief scientific officer for ophthalmology Stuart Naylor sold 27,659 ordinary shares of the company in open-market transactions. The sales occurred on July 7, 2026 at weighted average prices reported around $13.36 to $15.33 per share across multiple trades.
Following these transactions, Naylor directly holds 640,846 ordinary shares of MeiraGTx. The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the trades were scheduled in advance rather than timed opportunistically.
MGTX submitted a Form 144 notice reporting a proposed sale of 27,659 ordinary shares through Fidelity Brokerage Services LLC. The filing lists a gross value of $368,694.47 and references 07/07/2026 on NASDAQ. The record also shows a prior sale by Stuart Naylor of 27,661 shares on 04/07/2026 for $258,874.75.
MeiraGTx Holdings plc entered into a strategic financing with Oberland Capital for up to $400 million to fund late-stage gene therapy programs. The structure includes up to $375 million of senior secured royalty notes tied to capped low single-digit royalties on global net sales of AAV-AIPL1, AAV2-hAQP1 and bota-vec, plus up to $25 million of equity.
The first equity tranche covers 950,570 ordinary shares at $10.52 per share for about $10 million, with an additional $15 million purchase right. Royalty payments start quarterly after marketing approval and adjust after a December 31, 2031 test date based on how much of the funded amount has been repaid. MeiraGTx can voluntarily repurchase the notes and Oberland can require repurchase upon certain events of default.
The company used this transaction to redeem in full its outstanding Perceptive notes and related interest and fees, terminating that agreement without early termination penalties. MeiraGTx granted Oberland security interests over cash, equity interests, receivables, property, plant and equipment and specified assets related to the included products, and granted registration rights for resale of the new equity.
MeiraGTx Holdings plc granted its Chief Medical Officer, Robert K. Zeldin, 100,000 restricted share units (RSUs). Each RSU converts into one ordinary share upon vesting, so the award represents 100,000 underlying ordinary shares.
According to the vesting schedule, 50% of the RSUs will vest on the second anniversary of the grant date, with an additional 25% vesting on each of the third and fourth anniversaries. Following this grant, Zeldin is reported as holding 100,000 RSUs directly.
MeiraGTx Holdings plc reported that its General Counsel and Secretary, Robert J. Wollin, received a grant of 100,000 restricted share units. Each restricted share unit converts into one ordinary share upon vesting. Half the award vests on the second anniversary of the grant date, with 25% vesting on each of the third and fourth anniversaries.
Naylor Stuart reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc reported that Chief Scientific Officer of Ophthalmology Stuart Naylor received a grant of 70,000 Restricted Share Units. Each RSU represents the right to receive one ordinary share upon vesting. Half of the award vests on the second anniversary of the grant, with 25% vesting on each of the third and fourth anniversaries.